Table 2.

Dimensions of knowledge translation (knowledge gain; behavior modification)

Quantitative parameters	Qualitative parameters (following a structured interview guideline)
number of participants, response of questionnaires, use of training measures	• questions regarding user behavior • identification of barriers
knowledge gain measured by two questionnaires (pre- and post test)	• subjective evaluation of knowledge gain
"behavior modification screening" gathered by EBM2000plus (GOÄ):
• (03313 orientation survey of psychopathological status) • 03314 (857) mental tests • 03341 GP-geriatric basic assessment investigation at t2: assessment of 4 quarters before and 2 quarters after intervention	• self-evaluation of behavior • identification of barriers
„behavior modification diagnosis/differential diagnosis" assessed via six figures of ICD-10-GM 2005: F00, F01, F02, F03, F07, G32, R54 data gathered at t2: assessment of 4 quarters before and 2 quarters after intervention	• question whether diagnostic behavior has changed • identification of barriers
„behavior modification therapy" ascertained via prescriptions of anti-dementives*:
• cholinesterase inhibitors • memantine • ginkgo biloba compounds • piracetam investigation at t2: assessment of 4 quarters before and 2 quarters after intervention	• identify whether there is an increase in the prescription of evaluated anti-dementives (e.g. cholinesterase inhibitors, memantines) and whether there is a decrease in the prescription of untested or unreliable anti-dementives (e.g. ginkgo biloba compounds, piracetam) • question regarding future drug therapy • identification of barriers
„behavior modification treatment" gathered by EBM2000plus: 03001 coordination of GP-related care 03002 coordination of GP-related care in nursing homes 21230 continuous co-care in the domestic environment 21231 continuous co-care in a nursing facility 21232 psychiatric treatment investigation at t2: assessment of 4 quarters before and 2 quarters after intervention	• question regarding prescription of non drug-related therapy • question regarding support groups for family members • interaction with patients and family members when patient is suspected to suffer from dementia and when the diagnosis has been confirmed • identification of barriers

* Based on the most frequent prescriptions in Germany 2003 [77]